Summary by Moomoo AI
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will present at the TD Cowen 44th Annual Health Care Conference in Boston, MA, from March 4-6, 2024. The presentation, which will focus on Cybin's mission to revolutionize mental healthcare with psychedelic-based therapeutics, is scheduled for a live webcast on March 4, 2024, at 12:50 p.m. ET. Cybin is developing treatments for mental health conditions, including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, and is supported by a network of partners and scientists. The company, founded in 2019, operates in Canada, the US, the UK, the Netherlands, and Ireland.